查看文章

The first chimeric antigen receptor T cell (CAR-T) therapy in multiple myeloma (MM), idecabtagene vicleucel, directed against B-cell maturation antigen (BCMA), was approved in March 2021 for use in relapsed/refractory (RR) disease. In clinical trials, high response rates were reported with CAR-T therapy in heavily pretreated patients with MM [1-3]. In limited real-world experience since approval, the use of CAR-T therapy in patients with RRMM has also resulted in high response rates; however, the outcome of patients who were eligible for CAR-T therapy but did not receive it has not been studied [4]. We investigated the realworld experience of outcomes of patients with RRMM placed on commercial CAR-T therapy wait-list since its initial approval in March 2021. Methods including patients and disease variables along with statistical analysis were provided in supplementary. A total of 81 patients were listed for …